Logo

Pfizer's Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated- HER2-Negative LA or MBC

Share this

Pfizer's Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated- HER2-Negative LA or MBC

Shots:

  • The approval is based on EMBRACA trial results assessing Talzenna (1mg) vs CT in 431 patients with BRCA-mutated HER2-negative locally advanced or metastatic breast cancer for a duration of 11.2 mos.
  • EMBRACA study results: mPFS (8.6 mos. vs 5.6mos.); ORR (62.6% vs 27.7%); reduction in risk of death 46%
  • Talzenna (talazoparib) is an PARP (poly ADP ribose polymerase) inhibitor indicated for the treatment of patients with deleterious or suspected deleterious germline (inherited) BRCA-mutated HER2-negative LA or mBC in adults

Ref: Pfizer | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions